Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673083 · ClinicalTrials.gov registry record
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
A clinical trial of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by All4Cure.
- Active
- Registry status
- 200
- Enrollment target
- 7
- Study locations
NCT05673083 is a study of Multiple Myeloma and Multiple Myeloma in Relapse that is active but no longer recruiting, run by All4Cure. The registered enrollment target is 200 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05673083, a study of Multiple Myeloma and Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by All4Cure.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. * fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. * fill out a baseline and exit All4Cure surveys through the All4Cure website to assess patient perceptions of All4Cure at the beginning and the end of the study.
Conditions Studied
Study Locations (7)
Arkansas
- Highlands Oncology Group - Fayetteville
Florida
- Cancer Specialists of North Florida - Jacksonville
Iowa
- Misson Cancer + Blood - Des Moines
New York
- Hematology-Oncology Associates of Central New York - East Syracuse
Oklahoma
- Oklahoma Cancer Specialists and Research Institute - Tulsa
Texas
- Oncology Consultants - Houston
Washington
- Northwest Medical Specialties PLLC - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05673083
The ClinicalTrials.gov registry entry for NCT05673083 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower). The listed sponsor is All4Cure, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT05673083 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arkansas, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT05673083 about?
NCT05673083 is a clinical study titled "Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma". The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys ...
What is the current status of trial NCT05673083?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2023-03-01. Estimated completion is 2026-03.
What conditions does trial NCT05673083 study?
This clinical trial studies the following conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission.
Who is sponsoring clinical trial NCT05673083?
This trial is sponsored by All4Cure, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05673083 being conducted?
This trial has 7 study locations across Arkansas, Florida, Iowa, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.